Company: TXG
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001770787-25-000018
Chunk: 43

Company: 10x Genomics, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 43
---
. Our compensation committee considered the following six factors, as well as other factors it deemed relevant, in order to make its determination: (i) the provision of other services to us by Alpine Rewards; (ii) the amount of fees Alpine Rewards received from us, as a percentage of its total revenue; (iii) the policies and procedures of Alpine Rewards that are designed to prevent conflicts of interest; (iv) the lack of any business or personal relationships of the Alpine Rewards consultants with any member of our compensation committee; (v) the lack of any of our common stock owned by the Alpine Rewards consultants performing services for our compensation committee; and (vi) the lack of any business or personal relationships between the Alpine Rewards consultants or Alpine Rewards itself and any of our executive officers. Based on its review, our compensation committee determined that Alpine Rewards was independent, and that Alpine Rewards’ services did not raise any conflicts of interest.

#### Use of Competitive Data
Our compensation committee uses competitive compensation data as one factor in determining executive officer pay.

#### 10X GENOMICS, INC.442025 PROXY STATEMENT
For 2024, the committee reviewed data from a peer group selected to reflect companies similar to 10x Genomics in terms of sector, revenue, market capitalization, organizational complexity and geography. The 2024 peer group, listed below, was updated from the previous year by removing Adaptive Biotechnologies, Coupa Software (acquired), Invitae and Twist Bioscience, Inc. and adding Bio-Techne Corp., iRhythm Technologies, Inc. and Shockwave Medical, Inc. These changes continued to shift the focus toward the life sciences industry and reduced the number of software industry peers, in response to stockholder feedback.

The selected companies had annual revenues ranging from 0.5 to 3.0 times our trailing 12-month revenues and market capitalizations between 0.3 and 3.0 times our own. At the time of selection, we were positioned at the 35th percentile for trailing revenues, the 33rd percentile for revenue growth and the 67th percentile for market capitalization. Below is the list of peer companies used for 2024 compensation decisions.

| ACADIA Pharmaceuticals Inc. |     | Insulet Corporation                 |     | Penumbra, Inc.          |
| Alteryx, Inc.               |     | iRhythm Technologies, Inc.          |     | Repligen Corporation    |
| Azenta, Inc.                |